+10.82% · 1.83x volume · 56.01 > 52.93 > 51.57
Panel thesis: TEM wins on catalyst, participation and structure; extension remains a live objection.
Company context
Tempus AI, Inc. operates as a healthcare technology company in the United States.
Committee read
- Support — company-specific catalyst with 9.49% return and 4.74x time-relative volume
- Counter-case — the move is extended
- Unresolved — next-session follow-through.
Observed price path

Price channel and relative performance

Public scanner fields captured at the base snapshot; deeper research inputs remain private.
Snapshot
What was captured at the base
Structure
How price is behaving
Risk and context
What may change the read
Base framework for context and outcome tracking. These are not trading instructions.
Tracking results
Observed daily-bar ranges are retrospective measurements, not targets, stops, or trading instructions.
Tryding Review
Five AI analytical agents reading the same evidence; disagreement stays visible.
“TEM has a 9.49% move and 4.74x time-relative volume. That is attention, not proof.”
The falsifier is loss of VWAP with fading participation.
“The clinical result and Personalis acquisition create a candidate-specific mechanism.”
ANDG is credible, but TEM better explains why today.
Timeline
TEM tracked result improved 0.46 points to +0.90% as the stock gained 3.6% and held 0.29% above the session average, but participation was 1.08 times its three-month average and the move remains 2.3 ATR above its reference. Healthcare strength and accumulation keep the event-driven thesis alive; this is repair, not confirmation, until demand holds above the average price.
TEM's tracked result fell 3.2 points to -2.17% after the current capture dropped 8.97% on 1.55x volume and finished 2.73% below VWAP near the bottom of its range. Healthcare-relative strength and the event mechanism remain visible, but continuation has lost its price hold again; the catalyst survives while the follow-through case remains unresolved.
TEM tracked result fell 5.93 points since the last panel note to +1.03%. The current capture dropped 6.43% on 0.49x volume and finished 2.04% below the session average near the lower range; strong healthcare-relative performance keeps the event explanation visible, but continuation has lost its price hold.
TEM tracked result improved 6.04 points to +6.96%, with price 2.33% above the session average and participation still at 2.07x. The event-driven continuation thesis remains supported by the structure and strong healthcare outperformance, but RSI at 82.03 and decelerating participation make that support conditional rather than confirmed.
Panel thesis: TEM can continue its event-driven repricing while price holds VWAP and participation remains constructive. Invalidation boundary: A decisive loss of VWAP with fading participation invalidates the continuation thesis.
Panel comparison
Selected candidate versus the alternatives retained from the panel comparison.
Latest display-only snapshot · Aug 27, 2026 · 10:51 NASDAQGS
Since base +2.56% · Today +1.30% · Since prior +0.76% · Relative volume 0.14 · RSI 69.9 · EMA 64.69 > 59.01 > 54.95 · VWAP above +0.70% · 52-week high 66.50% · As of Aug 27, 2026 · 10:06 NASDAQGS
Since base +1.69% · Today -0.64% · Since prior 0.00% · As of Aug 20, 2026 · 17:01 NASDAQGS
Since base +2.26% · Today +1.09% · Since prior 0.00% · As of Aug 20, 2026 · 17:20 NASDAQGS
Since base -2.12% · Today -0.01% · Since prior 0.00% · As of Aug 20, 2026 · 17:19 NASDAQGS
Company dossier
History, curiosities & sources
Selected facts and links behind the public profile.
Company description
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.